EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Kaleido Biosciences, Inc (KLDO) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Kaleido Biosciences, Inc $0.00, price $0.00, upside +0.0%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US4833471000

KB Kaleido Biosciences, Inc logo Thin data Sep 27, 2026

Kaleido Biosciences, Inc

KLDO · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0001 · Fairly valued (+0.0%)
!Quality 38/100
!Mixed Growth (revenue YoY +13.2 %/yr)
!Moderate debt · negative free cash flow
!Mixed vs. peers (2/5)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Kaleido Biosciences, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.99 $0.0001 Fair Value $0.0001 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0001 – $7.99 · the $0.0001 price screens below the $0.0001 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Kaleido Biosciences in your weekly email

Every Wednesday you see whether Kaleido Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.

Show more

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Stock analysis

Kaleido Biosciences, Inc (KLDO) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kaleido Biosciences, Inc reported revenue of $1.1M in FY2021 versus $0 in FY2017. Reported net income was −$90.3M in FY2021.

Key figures

Market cap $4.2K · EPS (TTM) $−2.16 · Return on equity −581% · Return on assets (EBIT) −114% · Operating margin −3,974% · Revenue (TTM) $1.1M · Revenue growth (YoY) +103% · Free cash flow −$78.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 0%, KLDO screens richer than that median.

Fair Value models

Bear $0.0001 Fair Value $0.0001 Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0001 $0.0001 $0.0001 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0001 54

Open the full fair value analysis →

Notify me when KLDO reaches fair value

Put KLDO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 39 · Market factors (momentum, volatility) 37

Profitability 0
Margins and returns on capital today
Quality Growth 43
Are margins and returns improving?
Cashflow 31
Earnings quality: real cash, not paper profit
Fin. Strength 49
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2021 is a loss year, no rate is defined from a loss
not computed

Watch KLDO, get fair value alerts →

Compare Kaleido Biosciences, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 585 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside +0.0% · Top 25%
Profitability
Return on assets −99.9% · Bottom 25%
Growth and dividend
Revenue growth 102.5% · Top 25%
Balance sheet
Debt / equity 0.52× · Highest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)74 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kaleido Biosciences, Inc · Fair Value
$0.0001 +0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Kaleido Biosciences, Inc Fair Value". https://www.fairvalue-calculator.com/stock/KLDO

Frequently asked questions

Is Kaleido Biosciences, Inc (KLDO) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of KLDO?
Our model-based fair value for Kaleido Biosciences, Inc is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of KLDO?
Kaleido Biosciences, Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kaleido Biosciences, Inc (KLDO)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Kaleido Biosciences, Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Kaleido Biosciences, Inc (KLDO)?
Kaleido Biosciences, Inc reported trailing-twelve-month revenue of about $1.1M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Kaleido Biosciences, Inc (KLDO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kaleido Biosciences, Inc it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Kaleido Biosciences, Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, KLDO trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KLDO?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Kaleido Biosciences, Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kaleido Biosciences, Inc worth?
The market values Kaleido Biosciences, Inc at about $4.2K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Kaleido Biosciences, Inc (KLDO)?
Balance-sheet figures for Kaleido Biosciences, Inc (as of Sep 27, 2026): debt of 0.52 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is KLDO from its 52-week high?
Kaleido Biosciences, Inc trades at $0.0001, about 83% below its 52-week high of $0.0006 and at the low of $0.0001 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Kaleido Biosciences, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kaleido Biosciences, Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KLDO calculated?
We run Kaleido Biosciences, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Kaleido Biosciences, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kaleido Biosciences, Inc (KLDO)?
The closing price on Sep 30, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kaleido Biosciences, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Kaleido Biosciences, Inc

How large is the market capitalisation of Kaleido Biosciences, Inc (KLDO)?
The market capitalisation of Kaleido Biosciences, Inc is $4.2K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Kaleido Biosciences, Inc (KLDO)?
Earnings per share at Kaleido Biosciences, Inc are $−2.16. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Kaleido Biosciences, Inc (KLDO)?
The return on equity (ROE) of Kaleido Biosciences, Inc is −581% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kaleido Biosciences, Inc (KLDO)?
On an EBIT basis the return on assets of Kaleido Biosciences, Inc is −114% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kaleido Biosciences, Inc (KLDO)?
The operating margin of Kaleido Biosciences, Inc is −3,974% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kaleido Biosciences, Inc (KLDO)?
Revenue at Kaleido Biosciences, Inc is growing +103% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kaleido Biosciences, Inc (KLDO) generate?
The free cash flow of Kaleido Biosciences, Inc is −$78.2M (fiscal year 2021). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kaleido Biosciences, Inc (KLDO) hold?
Kaleido Biosciences, Inc holds more cash than debt, $16.8M net (fiscal year 2021). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kaleido Biosciences, Inc in the live analysis

One click puts Kaleido Biosciences, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.